annual CFF:
$294.16M+$122.03M(+70.89%)Summary
- As of today (May 29, 2025), ALNY annual cash flow from financing activities is $294.16 million, with the most recent change of +$122.03 million (+70.89%) on December 31, 2024.
- During the last 3 years, ALNY annual CFF has fallen by -$952.96 million (-76.41%).
- ALNY annual CFF is now -76.41% below its all-time high of $1.25 billion, reached on December 31, 2021.
Performance
ALNY Cash from financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly CFF:
$44.08M+$13.09M(+42.22%)Summary
- As of today (May 29, 2025), ALNY quarterly cash flow from financing activities is $44.08 million, with the most recent change of +$13.09 million (+42.22%) on March 31, 2025.
- Over the past year, ALNY quarterly CFF has increased by +$15.17 million (+52.48%).
- ALNY quarterly CFF is now -93.87% below its all-time high of $718.88 million, reached on March 31, 2014.
Performance
ALNY quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM CFF:
$309.33M+$15.17M(+5.16%)Summary
- As of today (May 29, 2025), ALNY TTM cash flow from financing activities is $309.33 million, with the most recent change of +$15.17 million (+5.16%) on March 31, 2025.
- Over the past year, ALNY TTM CFF has increased by +$154.66 million (+99.99%).
- ALNY TTM CFF is now -75.20% below its all-time high of $1.25 billion, reached on December 31, 2021.
Performance
ALNY TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash from financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
ALNY Cash from financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +70.9% | +52.5% | +100.0% |
| 3 y3 years | -76.4% | +26.1% | -74.9% |
| 5 y5 years | -64.3% | -18.2% | -36.4% |
ALNY Cash from financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -76.4% | +70.9% | -85.2% | +52.5% | -74.9% | +100.0% |
| 5 y | 5-year | -76.4% | +70.9% | -93.6% | +52.5% | -75.2% | +100.0% |
| alltime | all time | -76.4% | >+9999.0% | -93.9% | +313.0% | -75.2% | >+9999.0% |
ALNY Cash from financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2025 | - | $44.08M(+42.2%) | $309.33M(+5.2%) |
| Dec 2024 | $294.16M(+70.9%) | $31.00M(-69.8%) | $294.16M(-2.7%) |
| Sep 2024 | - | $102.75M(-21.9%) | $302.39M(+29.9%) |
| Jun 2024 | - | $131.50M(+354.8%) | $232.77M(+50.5%) |
| Mar 2024 | - | $28.91M(-26.3%) | $154.67M(-10.1%) |
| Dec 2023 | $172.13M(-59.6%) | $39.23M(+18.4%) | $172.13M(-12.3%) |
| Sep 2023 | - | $33.14M(-37.9%) | $196.34M(-57.3%) |
| Jun 2023 | - | $53.39M(+15.1%) | $460.23M(+5.3%) |
| Mar 2023 | - | $46.37M(-26.9%) | $437.17M(+2.7%) |
| Dec 2022 | $425.75M(-65.9%) | $63.44M(-78.6%) | $425.75M(-35.0%) |
| Sep 2022 | - | $297.02M(+879.1%) | $654.61M(-29.7%) |
| Jun 2022 | - | $30.34M(-13.2%) | $931.42M(-24.3%) |
| Mar 2022 | - | $34.96M(-88.0%) | $1.23B(-1.3%) |
| Dec 2021 | $1.25B(+25.3%) | $292.29M(-49.1%) | $1.25B(+6.3%) |
| Sep 2021 | - | $573.84M(+74.0%) | $1.17B(+85.2%) |
| Jun 2021 | - | $329.81M(+544.5%) | $633.09M(-36.2%) |
| Mar 2021 | - | $51.18M(-76.5%) | $992.29M(-0.3%) |
| Dec 2020 | $994.98M(+20.9%) | $217.95M(+538.3%) | $994.98M(+21.7%) |
| Sep 2020 | - | $34.15M(-95.0%) | $817.37M(+7.2%) |
| Jun 2020 | - | $689.01M(+1179.1%) | $762.52M(+56.9%) |
| Mar 2020 | - | $53.87M(+33.5%) | $486.12M(-40.9%) |
| Dec 2019 | $823.18M(+1157.3%) | $40.34M(-294.9%) | $823.18M(+4.4%) |
| Sep 2019 | - | -$20.70M(-105.0%) | $788.22M(-4.1%) |
| Jun 2019 | - | $412.61M(+5.5%) | $821.91M(+98.1%) |
| Mar 2019 | - | $390.93M(+7169.1%) | $414.88M(+533.7%) |
| Dec 2018 | $65.47M(-94.2%) | $5.38M(-58.6%) | $65.47M(-91.5%) |
| Sep 2018 | - | $12.99M(+132.7%) | $767.04M(-2.0%) |
| Jun 2018 | - | $5.58M(-86.6%) | $782.97M(-32.7%) |
| Mar 2018 | - | $41.52M(-94.1%) | $1.16B(+3.4%) |
| Dec 2017 | $1.12B(+532.6%) | $706.95M(+2344.9%) | $1.12B(+167.2%) |
| Sep 2017 | - | $28.91M(-92.5%) | $421.02M(+6.2%) |
| Jun 2017 | - | $386.31M(>+9900.0%) | $396.46M(+141.0%) |
| Mar 2017 | - | $2.72M(-11.9%) | $164.48M(-7.5%) |
| Dec 2016 | $177.83M(-71.1%) | $3.08M(-29.1%) | $177.83M(-1.9%) |
| Sep 2016 | - | $4.35M(-97.2%) | $181.22M(+0.4%) |
| Jun 2016 | - | $154.34M(+860.6%) | $180.52M(+442.8%) |
| Mar 2016 | - | $16.07M(+148.4%) | $33.26M(-94.6%) |
| Dec 2015 | $616.18M(-16.3%) | $6.47M(+77.2%) | $616.18M(-0.2%) |
| Sep 2015 | - | $3.65M(-48.4%) | $617.37M(-0.2%) |
| Jun 2015 | - | $7.07M(-98.8%) | $618.51M(+0.3%) |
| Mar 2015 | - | $598.98M(+7721.7%) | $616.57M(-16.3%) |
| Dec 2014 | $736.47M | $7.66M(+59.7%) | $736.47M(+0.0%) |
| Sep 2014 | - | $4.79M(-6.7%) | $736.46M(-0.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2014 | - | $5.14M(-99.3%) | $742.75M(+0.2%) |
| Mar 2014 | - | $718.88M(+9297.1%) | $741.59M(+269.1%) |
| Dec 2013 | $200.93M(+115.1%) | $7.65M(-31.0%) | $200.93M(+3.4%) |
| Sep 2013 | - | $11.08M(+178.4%) | $194.24M(+3.5%) |
| Jun 2013 | - | $3.98M(-97.8%) | $187.66M(+1.8%) |
| Mar 2013 | - | $178.21M(>+9900.0%) | $184.30M(+97.3%) |
| Dec 2012 | $93.41M(>+9900.0%) | $966.00K(-78.5%) | $93.41M(+0.8%) |
| Sep 2012 | - | $4.50M(+616.4%) | $92.71M(+5.1%) |
| Jun 2012 | - | $628.00K(-99.3%) | $88.21M(+0.2%) |
| Mar 2012 | - | $87.32M(>+9900.0%) | $88.05M(>+9900.0%) |
| Dec 2011 | $738.00K(-79.9%) | $267.00K(>+9900.0%) | $738.00K(-26.1%) |
| Sep 2011 | - | $0.00(-100.0%) | $998.00K(-5.0%) |
| Jun 2011 | - | $462.00K(+5033.3%) | $1.05M(-66.4%) |
| Mar 2011 | - | $9000.00(-98.3%) | $3.13M(-14.6%) |
| Dec 2010 | $3.66M(+4.4%) | $527.00K(+894.3%) | $3.66M(-2.9%) |
| Sep 2010 | - | $53.00K(-97.9%) | $3.77M(-15.8%) |
| Jun 2010 | - | $2.54M(+368.8%) | $4.48M(+16.7%) |
| Mar 2010 | - | $542.00K(-14.6%) | $3.84M(+9.5%) |
| Dec 2009 | $3.51M(+11.2%) | $635.00K(-16.8%) | $3.51M(-675.2%) |
| Sep 2009 | - | $763.00K(-59.9%) | -$610.00K(-360.7%) |
| Jun 2009 | - | $1.90M(+805.2%) | $234.00K(-93.9%) |
| Mar 2009 | - | $210.00K(-106.0%) | $3.84M(+21.6%) |
| Dec 2008 | $3.15M(-94.6%) | -$3.48M(-316.8%) | $3.15M(-57.3%) |
| Sep 2008 | - | $1.61M(-70.8%) | $7.39M(-88.4%) |
| Jun 2008 | - | $5.50M(-1266.1%) | $63.76M(+8.9%) |
| Mar 2008 | - | -$472.00K(-162.5%) | $58.56M(-0.1%) |
| Dec 2007 | $58.63M(-64.8%) | $755.00K(-98.7%) | $58.63M(-63.3%) |
| Sep 2007 | - | $57.97M(>+9900.0%) | $159.58M(+56.1%) |
| Jun 2007 | - | $303.00K(-176.5%) | $102.22M(-1.5%) |
| Mar 2007 | - | -$396.00K(-100.4%) | $103.75M(-37.7%) |
| Dec 2006 | $166.63M(+216.7%) | $101.70M(>+9900.0%) | $166.63M(+42.3%) |
| Sep 2006 | - | $617.00K(-66.4%) | $117.09M(+0.8%) |
| Jun 2006 | - | $1.84M(-97.1%) | $116.13M(+1.4%) |
| Mar 2006 | - | $62.48M(+19.8%) | $114.50M(+117.6%) |
| Dec 2005 | $52.62M(+3.2%) | $52.15M(<-9900.0%) | $52.62M(+777.8%) |
| Sep 2005 | - | -$343.00K(-265.7%) | $5.99M(-20.2%) |
| Jun 2005 | - | $207.00K(-65.6%) | $7.51M(-82.4%) |
| Mar 2005 | - | $602.00K(-89.1%) | $42.59M(-16.5%) |
| Dec 2004 | $50.98M(+115.0%) | $5.53M(+369.7%) | $50.98M(+12.2%) |
| Sep 2004 | - | $1.18M(-96.7%) | $45.45M(+2.7%) |
| Jun 2004 | - | $35.28M(+292.3%) | $44.27M(+392.3%) |
| Mar 2004 | - | $8.99M | $8.99M |
| Dec 2003 | $23.71M(+36.9%) | - | - |
| Dec 2002 | $17.32M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual CFF year-on-year change?
- What is Alnylam Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly CFF year-on-year change?
- What is Alnylam Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM CFF year-on-year change?
What is Alnylam Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of ALNY is $294.16M
What is the all time high annual CFF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual cash flow from financing activities is $1.25B
What is Alnylam Pharmaceuticals annual CFF year-on-year change?
Over the past year, ALNY annual cash flow from financing activities has changed by +$122.03M (+70.89%)
What is Alnylam Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of ALNY is $44.08M
What is the all time high quarterly CFF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly cash flow from financing activities is $718.88M
What is Alnylam Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, ALNY quarterly cash flow from financing activities has changed by +$15.17M (+52.48%)
What is Alnylam Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of ALNY is $309.33M
What is the all time high TTM CFF for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM cash flow from financing activities is $1.25B
What is Alnylam Pharmaceuticals TTM CFF year-on-year change?
Over the past year, ALNY TTM cash flow from financing activities has changed by +$154.66M (+99.99%)